Label Changes for:
Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – December 2011
- pyrexia, dehydration, pancytopenia, congestive heart failure, and left ventricular dysfunction
- Stevens-Johnson syndrome, toxic epidermal necrolysis and extravasation